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Plasmablastic lymphoma (PBL) is a rare form of diffuse
large B-cell lymphoma characterized by weak or absent
expression of conventional B-cell markers and strong
expression of plasma cell markers. It is strongly associated
with HIV and Epstein Barr Virus (EBV) infection, and
shows an unusual tropism to the oral cavity. Herein we
describe a patient with AIDS who presented with weight
loss and dysphagia owing to a large ulcerative gastro-
esophageal mass. His radiographic and endoscopic find-
ings and long history of cigarette consumption suggested
esophageal carcinoma. The patient had a history of multi-
drug resistant HIV and had been placed on salvage HAART
(tenofovir, emtricitabine, ritonavir and atazanavir).
Despite recent weight loss of 15 pounds, his CD4+ count
had improved from 50 to 180 cells/ìL and his HIV viral
load, previously >100,000 copies/ml was now undetecta-
ble. Biopsy demonstrated a poorly differentiated tumor
staining negatively to routine lymphoid markers includ-
ing CD20. However, gene rearrangement studies con-
firmed a B-cell process and a more detailed
immunohistochemistry analysis revealed the cells
expressing CD138 (plasma cell antigen). In situ hybridi-
zation studies were positive for EBV but negative for
Human Herpes Virus type-8. These findings were diagnos-
tic of PBL and the patient was treated with combination
chemotherapy consisting of liposomal doxorubicin,
cyclophosphamide and etoposide. After six cycles of
chemotherapy, his dysphagia and weight loss resolved
and a positron emission tomogram showed complete res-
olution of the esophagogastric mass. The patient remains
in complete remission 12 months later.
Our report underscores the importance of a broad array of
viral and molecular studies needed to establish the diag-
nosis of PBL, which may mimic a variety of entities
including carcinoma, melanoma, Kaposi's sarcoma, plas-
macytoma and primary effusion lymphoma. Further-
more, our patient's diagnosis of lymphoma within 1 year
of HAART initiation, and in the context of a rapidly
improving CD4+ cell count and non-detectable HIV viral
load may represent a case of immune reconstitution syn-
drome associated Non-Hodgkin's lymphoma.
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